stockrow
Friday 6 November 2026
Export MDGL’s income statement to Excel — free account
Madrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
396.86
3.24
−0.81%
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) Revenue growth
Madrigal Pharmaceuticals, Inc.'s revenue growth over the twelve months to 30 September 2026 was 92.8%, down 339.2 percentage points from fiscal 2025 (432.1%). That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 432.1% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 50.1% | (21.04) |
| Jun 2026 | 71.2% | (55.67) |
| Mar 2026 | 126.8% | (83.93) |
| Dec 2025 | 210.8% | (151.26) |
| 2 more quarters | Free account |
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| IBRX ImmunityBio, Inc. compare | 192.9% |
| MDGL Madrigal Pharmaceuticals, Inc. | 92.8% |
| TGTX TG Therapeutics, Inc. compare | 76.1% |
| CAI Caris Life Sciences,�Inc. compare | 68.8% |
| PTGX Protagonist Therapeutics, Inc. compare | 34.8% |
| CYTK Cytokinetics, Incorporated compare | 29.9% |
| KRYS Krystal Biotech, Inc. compare | 26.0% |
| TWST Twist Bioscience Corporation compare | 19.2% |
| SYRE Spyre Therapeutics, Inc. compare | −81.8% |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on MDGL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement